-
[show abstract]
[hide abstract]
ABSTRACT: The objective of this study was to evaluate the clinical effect of endovascular treatment on postoperative blood pressure (BP) control and kidney function of hypertensive patients with renal artery stenosis (RAS). Between January 2004 and December 2011, RAS was diagnosed in 120 renal arteries from 115 hypertensive patients. Preoperative and postoperative BPs and glomerular filtration rate (GFR) were monitored. Postoperative oral antiplatelet and antihypertensive agents were administered. Clinical follow-up was available for all patients for at least 6 months. Balloon angioplasty was performed successfully in 110 patients, and stents were deployed in 94 renal arteries from 89 patients. Hypertension was cured and lessened in 19 and 61 patients, respectively. Blood pressure was stable and worsened in 26 and 9 patients, respectively. The renal function was improved and stable in 23 patients and 57 patients, respectively. Deterioration of renal function was observed in 11 patients. Doppler ultrasound after discharge revealed 87 patent renal arteries and fixed stents in 82 patients 6 months after procedure. Balloon angioplasty and stent deployment are effective and feasible procedures for patients with RAS that help in controlling BP and improving renal function moderately.
Clinical and Experimental Hypertension 10/2012; · 1.07 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: We wanted to evaluate the feasibility of catheter-directed thrombolysis with a continuous infusion of low-dose urokinase for treating non-acute (less than 14 days) deep venous thrombosis of the lower extremity.
The clinical data of 110 patients who were treated by catheter-directed thrombolysis with a continuous infusion of low-dose urokinase for lower extremity deep venous thrombosis was analysed. Adjunctive angioplasty or/and stenting was performed for the residual stenosis. Venous recanalization was graded by pre- and post-treatment venography. Follow-up was performed by clinical evaluation and Doppler ultrasound.
A total of 112 limbs with deep venous thrombosis with a mean symptom duration of 22.7 days (range: 15-38 days) were treated with a urokinase infusion (mean: 3.5 million IU) for a mean of 196 hours. After thrombolysis, stent placement was performed in 25 iliac vein lesions and percutaneous angioplasty (PTA) alone was done in five iliac veins. Clinically significant recanalization was achieved in 81% (90 of 112) of the treated limbs; complete recanalization was achieved in 28% (31 of 112) and partial recanalization was achieved in 53% (59 of 112). Minor bleeding occurred in 14 (13%) patients, but none of the patients suffered from major bleeding or symptomatic pulmonary embolism. During follow-up (mean: 15.2 months, range: 3-24 months), the veins were patent in 74 (67%) limbs. Thirty seven limbs (32%) showed progression of the stenosis with luminal narrowing more than 50%, including three with rethrombosis, while one revealed an asymptomatic iliac vein occlusion; 25 limbs (22%) developed mild post-thrombotic syndrome, and none had severe post-thrombotic syndrome. Valvular reflux occurred in 24 (21%) limbs.
Catheter-directed thrombolysis with a continuous infusion of low-dose urokinase combined with adjunctive iliac vein stenting is safe and effective for removal of the clot burden and for restoration of the venous flow in patients with non-acute lower extremity deep venous thrombosis.
Korean journal of radiology: official journal of the Korean Radiological Society 01/2011; 12(1):97-106. · 1.32 Impact Factor
-
Xueying Sun,
Haiquan Qiao,
Hongchi Jiang,
Xuting Zhi,
Fengjun Liu,
Jianli Wang,
Meng Liu, Dianning Dong,
Jagat R Kanwar,
Ruian Xu,
Geoffrey W Krissansen
[show abstract]
[hide abstract]
ABSTRACT: The success of surgery to remove primary tumors can be compromised by the subsequent outgrowth of metastases. It is recognized that primary tumors secrete antiangiogenic factors that suppress the outgrowth of their daughter metastases. In accord we show here that surgical removal of primary EL-4 lymphomas led to a marked decrease in the levels of circulating angiostatin and endostatin, and promoted the growth of distant nodular tumors. Expression vectors encoding angiostatin and endostatin, formulated with poly-N-vinyl pyrrolidone (PVP), were injected into the tibialis and gastrocnemia muscles, leading to expression of angiostatin and endostatin in muscle fibers. High levels of biologically active exogenous proteins were secreted into the circulation. Intramuscular gene therapy with angiostatin and endostatin plasmids significantly inhibited tumor vascularity and induced tumor cell apoptosis, and thereby suppressed the growth of secondary subcutaneous and disseminated metastatic tumors in the lung and liver. Simultaneous intramuscular delivery of both angiostatin and endostatin plasmids significantly prolonged the survival of mice after removal of primary tumors. These results suggest that intramuscular gene transfer of angiostatin and endostatin might serve as a prophylactic cancer-prevention strategy to combat the recurrence of cancer after surgical resection of primary tumors.
Cancer Gene Therapy 02/2005; 12(1):35-45. · 2.80 Impact Factor
